Spinal Muscular Atrophy Market to Reach $7.34 Billion by 2030 at 12.9% CAGR

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Estimated Market Size Of The Spinal Muscular Atrophy Market In 2026, And How Will Its Value Evolve By 2030?

The spinal muscular atrophy market has seen a rapid expansion in its size over recent years. Forecasts show an increase from $4 billion in 2025 to $4.53 billion in 2026, achieving a compound annual growth rate (CAGR) of 13.2%. This growth during past periods can be primarily linked to the approval of breakthrough sma therapies, an increase in genetic testing, greater advocacy group awareness, substantial clinical trial investments, and consistent rare disease funding.

The spinal muscular atrophy market is projected to experience substantial growth in the upcoming years. It is expected to expand to $7.34 billion by 2030, achieving a compound annual growth rate (CAGR) of 12.9%. The expansion during this forecast period stems from factors such as next-generation gene therapies, the widespread adoption of global screening, increased availability of treatments, better survival outcomes, and the progress in pipeline drug development. Noteworthy trends during the forecast period include the emphasis on early genetic diagnosis, the growth of disease-modifying therapies, the implementation of newborn screening programs, the creation of personalized treatment protocols, and comprehensive long-term disease management.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20965&type=smp

What Significant Factors Are Influencing The Spinal Muscular Atrophy Market Expansion?

An anticipated increase in rare genetic diseases is poised to fuel the expansion of the spinal muscular atrophy market. These diseases are defined as conditions stemming from gene mutations, impacting a small demographic and frequently leading to severe, long-term health issues. This rise in prevalence is linked to advancements in diagnostic tools, heightened public awareness, and wider availability of genetic testing, resulting in more identified and reported cases. Spinal muscular atrophy (SMA), itself a rare genetic disorder, serves as an example of the complexities and prospects in comprehending inherited diseases, underscoring the vital need for progress in genetic research. For example, data from July 2023, from a report by the Office for National Statistics, a UK-based government department, indicated that SMN1 genetic testing has facilitated accurate epidemiological studies, showing SMA affects 1 of 10,000 to 20,000 live births, with over 95% of patients having homozygous SMN1 deletion. Consequently, the growing occurrence of rare genetic diseases is set to drive the expansion of the spinal muscular atrophy market.

What Are The Key Segment Divisions In The Spinal Muscular Atrophy Market Segment Structure?

The spinal muscular atrophy market covered in this report is segmented –

1) By Type: Type 1 (Severe), Type 2 (Intermediate), Type 3 (Mild), Type 4 (Adult)

2) By Age: Pediatric, Adults

3) By Treatment: Drug Therapy, Gene Therapy

4) By End User: Hospital pharmacy, Online pharmacy, Retail pharmacy

Subsegments:

1) By Type 1 (Severe): Infantile-Onset SMA, Severe Progressive SMA

2) By Type 2 (Intermediate): Early-Onset SMA, Non-progressive SMA

3) By Type 3 (Mild): Juvenile-Onset SMA, Mild Progressive SMA

4) By Type 4 (Adult): Adult-Onset SMA, Late-Onset SMA

What Trends Are Affecting The Direction Of The Spinal Muscular Atrophy Market?

Companies operating within the spinal muscular atrophy market are actively developing innovative solutions, such as dry syrup, to boost medication adherence and ease of administration for pediatric patients and other groups who encounter swallowing difficulties. Dry syrup is a powdered medication that requires reconstitution with water before consumption and is commonly prescribed for children and individuals struggling to swallow tablets or capsules. For example, in September 2024, Chugai Pharmaceutical Co., Ltd., a pharmaceutical company based in Japan, announced that Japan’s Ministry of Health, Labour and Welfare had granted regulatory approval for an expanded indication of its drug Evrysdi (risdiplam). This approval extends its use to pre-symptomatic spinal muscular atrophy (SMA) and allows dosing for infants under two months old. This achievement is significant because it enables treatment to begin before symptoms manifest, potentially leading to improved therapeutic outcomes for affected infants. The decision was supported by findings from the RAINBOWFISH study, which evaluated Evrysdi’s safety and efficacy in infants diagnosed with SMA who were not yet symptomatic. Results indicated that treated infants reached developmental milestones, including unsupported sitting and enhanced motor skills, by 12 months, thereby emphasizing the drug’s potential to alter the disease’s progression when administered early.

Which Organizations Are Engaged In The Spinal Muscular Atrophy Market?

Major companies operating in the spinal muscular atrophy market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Bayer AG, Novartis AG, Biogen Inc., Chugai Pharmaceutical Co. Ltd., Genentech Inc., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., RegenXBio Inc., Cytokinetics Inc., AveXis Inc., Scholar Rock Inc., Genethon, CANbridge Pharmaceuticals Inc., NMD Pharma A/S, Hanugen Therapeutics Inc., Beijing Jinlan Gene Technology Co. Ltd, Sarepta Therapeutics, Amicus Therapeutics, Audentes Therapeutics, Solid Biosciences

Get The Full Spinal Muscular Atrophy Market Report:

https://www.thebusinessresearchcompany.com/report/spinal-muscular-atrophy-global-market-report

Which Region Dominates The Spinal Muscular Atrophy Market By Market Share?

North America was the largest region in the spinal muscular atrophy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the spinal muscular atrophy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Spinal Muscular Atrophy Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/spinal-muscular-atrophy-global-market-report

Browse Through More Reports Similar to the Global Spinal Muscular Atrophy Market 2026, By The Business Research Company

Spine Biologics Market Report 2026

https://www.thebusinessresearchcompany.com/report/spine-biologics-global-market-report

Muscle Wasting Disorders Market Report

https://www.thebusinessresearchcompany.com/report/muscle-wasting-disorders-global-market-report

Duchenne Muscular Dystrophy Dmd Therapeutics Market Report

https://www.thebusinessresearchcompany.com/report/duchenne-muscular-dystrophy-dmd-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795